SYGNIS Signs Non-Exclusive Distribution Agreement with SOPACHEM
News Mar 19, 2015
SYGNIS AG has announced a distribution agreement with SOPACHEM for the commercialization of the TruePrime™ product family developed by SYGNIS and designed for whole genome amplification (WGA) in Belgium.
Under the terms of the agreement, SOPACHEM will promote, market, sell and support TruePrime™ products for primer-free WGA in Belgium. TruePrime™ is based on SYGNIS’ revolutionary novel multiple displacement amplification (MDA) technology addressing key challenges in NGS applications, increasingly demanded in fields such as oncology, pathology and clinical diagnostics.
SOPACHEM is a specialized distributor with a strong focus on life sciences, diagnostics, biobanking and analytical applications with a broad portfolio of innovative products and technologies for NGS, polymerase chain reaction (PCR) analysis, DNA extraction and purification, transfection, bio-imaging and instrumentation. Besides its headquarters in Belgium, SOPACHEM runs additional offices in the Netherlands and in Luxembourg.
TruePrime™ WGA products are available in two formats, containing 25 or 100 reactions. Beside the worldwide commercialization via a fast growing list of leading international distribution partners, the product is made available and can also be directly ordered through SYGNIS’ own TruePrime™ online shop under www.sygnis.com/shop.
"Non-Gene" Mutations May Hold Answers to Neurodevelopmental DisordersNews
Mutations in non-coding regions of the genome, which don't contain genes, but control the regulation of other genes, may hold answers to rare developmental disorders that affect the nervous system.READ MORE
Majority of European Wolves Have Dog DNANews
The wolf may not often act like man's best friend, but a new study has found that the majority of wild wolves in Europe contain chunks of dog DNA. The finding is causing scientists to rethink what constitutes a wolfdog hybrid and how we approach conservation of keystone wolf populations.READ MORE